Trial Profile

Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Furaprevir (Primary) ; Interferon alpha-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors TaiGen Biotechnology

Most Recent Events

12 Oct 2017 Status changed from active, no longer recruiting to completed.
17 Oct 2016 Part B of the trial (to evaluate the antiviral efficacy of 8-week treatment of TG-2349 +IFN+RBV, with or without an additional 12-week treatment of IFN+RBV) has been deleted; number of treatment arms changed from 4 to 2.
17 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com